2023
Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?
Bewersdorf J, Huntington S, Zeidan A. Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future? Journal Of The National Comprehensive Cancer Network 2023, 21: 522-528. PMID: 37037494, DOI: 10.6004/jnccn.2023.70012.Peer-Reviewed Original ResearchConceptsCost-effectiveness analysisEconomic modeling techniquesCost-effectiveness studiesFinite financial resourcesDrug pricesHealth policy decisionsPolicy decisionsFinancial resourcesResource allocationUnited StatesPublic interestCostHealthcare systemPricesSuch analysesLimited resourcesAllocationCountriesConsumersData sourcesPayersAssumptionBenefitsBudgetary considerationsDifferent interventions
2020
Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma
Patel K, Parker T, Di M, Bar N, Huntington S, Giri S. Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma. Blood 2020, 136: 51-52. DOI: 10.1182/blood-2020-141972.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioQuality-adjusted life yearsBest supportive careRefractory multiple myelomaMultiple myelomaSupportive careProbabilistic sensitivity analysesDisease progressionIncremental effectivenessIncremental costPost-progression therapyTwice-weekly bortezomibLarge randomized trialsProgression-free survivalUS payer perspectiveIncremental lifetime costOne-way sensitivity analysesCost-effectiveness ratioQuality of lifeCost of treatmentCost-effectiveness analysisVD progressionAnnual discount rateAdverse eventsHazard ratio
2018
Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma
Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. Journal Of Clinical Oncology 2018, 36: jco.18.00122. PMID: 30285558, PMCID: PMC6241679, DOI: 10.1200/jco.18.00122.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioFirst-line settingFirst-line therapyBrentuximab vedotinHodgkin's lymphomaHealth care costsStage IIICare costsDirect health care costsLifetime health care costsOpen-label trialCohort of patientsRisk of progressionUS payer perspectiveMarkov decision-analytic modelCost-effectiveness ratioDecision analytic modelFavourable cost effectivenessCost-effectiveness analysisStandard ABVDClinical outcomesPayer perspectiveParametric survival distributionsIndication-specific pricingCost effectiveness
2015
Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission
Huntington SF, Svoboda J, Doshi JA. Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission. Journal Of Clinical Oncology 2015, 33: 1467-1474. PMID: 25823735, DOI: 10.1200/jco.2014.58.5729.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisDecision Support TechniquesFluorodeoxyglucose F18Health Care CostsHumansImmunotherapyLymphoma, Large B-Cell, DiffuseMarkov ChainsMiddle AgedModels, EconomicMultimodal ImagingPositron-Emission TomographyPredictive Value of TestsQuality-Adjusted Life YearsRadiopharmaceuticalsRemission InductionTime FactorsTomography, X-Ray ComputedTreatment OutcomeConceptsDiffuse large B-cell lymphomaQuality-adjusted life yearsIncremental cost-effectiveness ratioLarge B-cell lymphomaB-cell lymphomaComputed tomographySurveillance imagingCost-effectiveness analysisSurveillance strategiesFirst remissionFluorodeoxyglucose positron emission tomography-computed tomographyPositron emission tomography-computed tomographyEmission tomography-computed tomographyPET/CT scansPET/Computed TomographyFirst-line immunochemotherapyRoutine surveillance imagingMinimal survival benefitDecision-analytic Markov modelLittle clinical benefitRoutine computed tomographyImproved clinical outcomesTomography-computed tomographyCost-effectiveness ratioProbabilistic sensitivity analyses